HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.

Abstract
Previous studies have shown that gene therapy with inducible nitric oxide synthase (iNOS) protects against myocardial infarction at 3 days after gene transfer. However, the long-term effects of iNOS gene therapy on myocardial ischemic injury and cardiac function are unknown. To address this issue, we used a recombinant adenovirus 5 (Ad5) vector (Av3) with deletions of the E1, E2a, and E3 regions, which enables long-lasting recombinant gene expression for at least 2 mo due to lack of inflammation. Mice received intramyocardial injections in the left ventricular (LV) anterior wall of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 1 or 2 mo later, they were subjected to myocardial infarction (30-min coronary occlusion followed by 4 h of reperfusion). Cardiac iNOS gene expression was confirmed by immunoblotting and activity assays at 1 and 2 mo after gene transfer. In the iNOS group, infarct size (percentage of risk region) was significantly reduced (P < 0.05) both at 1 mo (24.2 +/- 3.4%, n = 6, vs. 48.0 +/- 3.6%, n = 8, in the LacZ group) and at 2 mo (23.4 +/- 3.1%, n = 8, vs. 36.6 +/- 2.4%, n = 7). The infarct-sparing effects of iNOS gene therapy were as powerful as those observed 24 h after ischemic preconditioning (23.1 +/- 3.4%, n = 10). iNOS gene transfer had no effect on LV function or dimensions up to 8 wk later (echocardiography). These data demonstrate that iNOS gene therapy mediated by the Av3 vector affords long-term (2 mo) cardioprotection without inflammation or adverse functional consequences, a finding that provides a rationale for further preclinical testing of this therapy.
AuthorsQianhong Li, Yiru Guo, Wei Tan, Adam B Stein, Buddhadeb Dawn, Wen-Jian Wu, Xiaoping Zhu, Xiaoqin Lu, Xiaoming Xu, Tariq Siddiqui, Sumit Tiwari, Roberto Bolli
JournalAmerican journal of physiology. Heart and circulatory physiology (Am J Physiol Heart Circ Physiol) Vol. 290 Issue 2 Pg. H584-9 (Feb 2006) ISSN: 0363-6135 [Print] United States
PMID16172153 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Cardiotonic Agents
  • Nitric Oxide Synthase Type II
Topics
  • Animals
  • Cardiotonic Agents (metabolism)
  • Echocardiography
  • Gene Expression
  • Genetic Therapy
  • Heart (physiopathology)
  • Male
  • Mice
  • Mice, Inbred ICR
  • Myocardial Infarction (diagnostic imaging, pathology, physiopathology)
  • Myocardium (enzymology, pathology)
  • Nitric Oxide Synthase Type II (genetics, metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: